



# 2024 Annual Results Announcement

The United Laboratories International Holdings Limited (3933.HK)

March 2025



# Disclaimer



This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2024 annual results announcement and other relevant announcements published on the website of the Stock Exchange of Hong Kong ([www.hkexnews.hk](http://www.hkexnews.hk)) for further information.

By reading these materials, you agree to be bound by the following limitations:

The information herein has been prepared by representatives of The United Laboratories International Holdings Limited (the “Company” or “TUL”) solely for your information and have not been independently verified. The information herein does not constitute any recommendation regarding any securities of the Company.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. The Company, nor any of their respective affiliates, controlling persons, directors, officers, employees, advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of the information herein or its contents or otherwise arising in connection with the information herein. The information or opinions set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially without notice and shall only be considered current as of the date hereof. The information herein is based on the economic, regulatory, market and other conditions as in effect on the date hereof. Certain information in the materials contain information may be sourced from third parties, which has not been independently verified by the Company. It should be understood that any subsequent developments may affect the information contained herein, which the Company is not under an obligation to update, revise or affirm.

You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company and any of its subsidiaries.







# Section 1

---

Annual Snapshot



# 2024 Annual Results Snapshot



# Business Snapshot



## Business Highlights

Prudent Management  
Continuous Dividend Payouts

- Sales revenue from intermediate products increased by 14.8% YoY
- Sales revenue from animal healthcare products increased by 17.1% YoY
- Established a finished products marketing team, under a new management framework of medical market, OTC market and broader market
- Established Healthcare Products Division in 2024, committed to continuously establishing iconic brands in the health consumption sector
- This year's dividend payout ratio rose to 38.3%



## Significant Advancements

Strengthen Partnerships  
Expand Globally

- Entered an Exclusive License Agreement with Novo Nordisk for UBT251 in Mar 2025
- Human insulin won a tender from Ministry of Health (Brazil)
- Continued to promote overseas expansion for animal health products and obtained several overseas registration approvals
- Signed a Strategic Cooperation Agreement with Sinopharm Group to enhance the cooperative marketing of all product series
- Partnered with New Zealand Riverland Foods to expand reach in the premium pet food sector



## Innovation & R&D

Number of Class 1 New Drug  
in Development  
**22**


- Liraglutide injection received marketing approval in Mar 2025
- The marketing applications for semaglutide injection and insulin degludec injection have been accepted
- UBT251 Injection:
  - Phase Ib clinical trial was completed in China in Jan 2025;
  - Clinical trials for CKD indication were approved in China and the U.S. respectively in Jan and Mar 2025
- The first subject has been enrolled in the Phase II clinical trial for TUL01101 Tablets /Ointment & TUL12101 Eye Drops



## Sustainable Development

MSCI ESG rating  
**A**

- Pursuant to the 2023 Share Award Scheme, a total of 3,606,180 award shares of the first tranche have been granted
- Focused on talent development to build a professional, efficient, and innovative team
- The Inner Mongolia base has initiated projects for salt fractionation and acid-alkali conversion, as well as biogas incineration waste recovery and utilization, to actively build green factories
- Aligned with international standards to consistently enhance the quality system



## United Biotechnology Enters an Exclusive License Agreement with Novo Nordisk for UBT251, a Triple Agonist of GLP-1R/GIPR/GCGR

### ✓ Scope of Rights

#### United Biotechnology

Will retain the rights in Chinese mainland, Hong Kong, Macau and Taiwan

#### Novo Nordisk

Will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau and Taiwan) to develop, manufacture and commercialise UBT251

### ✓ Financial Terms



An upfront payment of **USD200 million**



Milestone payments of up to **USD1.8 billion**




Tiered royalties on annual aggregate net sales

## UBT251

- **Class I new drug**
- GI hormone analogue with **multi-target (GLP-1/GCG/GIP)** effect
- **The first enterprise in China and the second in the world** to be approved for clinical trials of such analogue prepared by chemical synthesis polypeptide method
- Clinical indications approved for clinical trials:
  - T2DM (China, the U.S.)
  - Overweight/Obesity (China, the U.S.)
  - Chronic Kidney Disease (CKD) (China, the U.S.)
  - Metabolic Associated Fatty Liver Disease (MAFLD)



# Overseas Footprint



**RMB11,115.6 Million**  
Revenue in China

**80.8%**  
of Total Revenue



**RMB2,643.4 Million**  
Overseas Revenue

**19.2%**  
of Total Revenue

- Covers nearly 80 countries and regions globally, including Europe, India, the Middle East, South America, Southeast Asia, and others
- Obtained official approvals and certifications including EDQM, U.S. FDA, Germany, India, Brazil, Mexico and other regions



- Our strategy will center on diabetes products, with a key focus on expansion into markets of the "Belt and Road" Initiative



- Won the human insulin procurement bid from the Ministry of Health (Brazil) in 2024



- Received 6 animal healthcare product registration approvals in Vietnam and Australia







# Section 2

---

## Financial Highlights






# Financial Overview



RMB million	2024	2023	y-o-y change	1H2024	2H2024
<b>Revenue</b>	<b>13,758.9</b>	13,739.9	+0.1%	7,175.8	6,583.1
<b>Gross profit</b>	<b>6,082.4</b>	6,334.8	-4.0%	3,344.4	2,738.0
<b>EBITDA</b>	<b>3,939.4</b>	3,976.7	-0.9%	2,231.9	1,707.5
<b>Profit attributable to owners of the Company</b>	<b>2,659.7</b>	2,701.4	-1.5%	1,491.4	1,168.3
<b>Earnings per share (RMB cents)</b>					
- Basic	<b>146.39</b>	148.67	-1.5%	82.08	64.31
<b>Dividend per share (RMB cents)</b>					
-Interim dividend	<b>16.0</b>	12.0	+33.3%		
-Final dividend	<b>28.0</b>	28.0	+0%	--	--
-Special dividend	<b>12.0</b>	12.0	+0%		
<b>Annual dividend payout ratio</b>	<b>38.3%</b>	35.0%	+3.3p.p.	--	--

# Segment Business



RMB million	Intermediate Products		Bulk Medicine		Finished Products	
	2024	2023	2024	2023	2024	2023
<b>Segment profit before R&amp;D expenses</b>	<b>2,215.3</b>	2,098.2	<b>904.6</b>	969.4	<b>889.3</b>	1,044.4
<b>Segment profit</b>	<b>2,101.4</b>	1,984.5	<b>704.9</b>	781.8	<b>312.1</b>	588.5
<b>Segment margin</b>	<b>35.9%</b>	34.5%	<b>9.6%</b>	10.6%	<b>6.6%</b>	11.7%

Note: Segment profit includes intersegment sales

## Other Key Financial Indicators



	As at 31 Dec 2024	As at 31 Dec 2023
<b>Current ratio</b>	<b>1.83</b>	2.08
<b>Net current assets (RMB million)</b>	<b>7,298.1</b>	7,160.5
<b>Net cash position<sup>#</sup> (RMB million)</b>	<b>2,139.7</b>	1,755.5
<b>Cash and cash equivalents (RMB million)</b>	<b>6,329.8</b>	4,262.0
<b>Total assets (RMB million)</b>	<b>25,833.1</b>	21,017.2

*<sup>#</sup> Net cash position denotes the Group's net cash and bank balances after deducting borrowings and trade payables under supplier finance arrangement (mainly refer to bills payables).*

	2024	2023
<b>Net cash from operating activities (RMB million)</b>	<b>3,199.3</b>	2,439.4



# Section 3

---


## Business Review





# Finished Products – Revenue Breakdown

In 2024, sales revenue from finished products decreased by 5.9% to RMB4,727.6 million, accounting for 34.4% of the Group's total external sales



- Semi-synthetic penicillins antibiotics: -4.6% to RMB632.6 million
- Cephalosporins antibiotics: -10.7% to RMB175.0 million
- $\beta$ -lactamase inhibitors antibiotics: -44.8% to RMB553.9 million
- Carbapenems antibiotics: -9.9% to RMB259.1 million
- Insulin Series: +10.1% to RMB1,236.4 million #
- Animal Healthcare: +17.1% to RMB1,382.2 million
- Others: -14.7% to RMB488.4 million


Revenue Breakdown of Finished Products in 2024

# Sales revenue denotes gross sales including sales discounts



# Finished Products – Insulin Series

Sales Revenue of Insulin# (RMB million)



# Sales revenue denotes gross sales including sales discounts

## USLIN

Recombinant Human Insulin Injection



- Launched in 2009
- Including four specifications: N, R, 30R and 50R

## USLEN

Insulin Glargine Injection



- Launched in 2016
- Long-acting insulin with steady blood glucose control

## UBLIN

Insulin Aspart / Insulin Aspart 30 Injection



- Launched in 2021
- Fast-acting insulin analogue with rapid onset of action





# Finished Products – Antibiotics

- ✓ Including oral and injectable antibiotic products of penicillins, cephalosporins,  $\beta$ -lactamase inhibitors and carbapenems
- ✓ Sales revenue from antibiotic products (including Animal Healthcare) decreased by 10.0% to RMB3,179.6 million in 2024



阿莫仙

**Amoxicillin Capsules**

Sales revenue decreased by 2.8% to RMB531.4 million

他唑仙

**Piperacillin Sodium and Tazobactam Sodium for Injection**

Sales revenue decreased by 56.5% to RMB294.0 million

倍能安

**Imipenem and Cilastatin Sodium for Injection**

Sales revenue decreased by 8.0% to RMB258.6 million

赛乐林

**Roxithromycin Capsules**

Sales revenue increased by 2.6% to RMB89.5 million

强力阿莫仙

**Amoxicillin and Clavulanate Potassium for Suspension**

Sales revenue decreased by 25.1% to RMB210.8 million

# Finished Products – Healthcare



- ✓ Launched 18 products, covering 5 major product lines of general dietary supplements, health foods, cross-border nutritional supplements, medical devices and medical aesthetic skincare
- ✓ In 2024, sales revenue from Healthcare Products reached RMB19.97 million



## Build a Healthy Consumer Brand

- Healthcare Product Division established in 2024
- Embrace an “Omni-channel, all fields, and all people” strategy
- Committed to continuously establishing iconic brands in the health consumption sector

## Diverse Product Portfolio

- Cardiovascular Health
- Bone and Joint Nutrition
- Intestinal Regulation
- Vision Protection
- Immune Regulation
- Skin Whitening & Anti-aging
- Vital Energy and Blood Nourishment

## Optimize Sales Network

- Online platform matrix encompassing e-commerce, live streaming, and new retail channel
- Products are available on Tmall, JD.com, Douyin, Kuaishou, WeChat Store and Rednote
- Coverage of over 9,000 chain pharmacies and health-focused vertical channels



# Finished Products – Animal Healthcare

- ✓ Mainly engaged in the R&D, production and sales of veterinary drugs used in economic and companion animals
- ✓ A full range of  $\beta$ -lactams products and a leading position in penicillin-based veterinary drugs
- ✓ Establish production bases in Southern, Northern and Central China, forming a nationwide network
- ✓ Expand strategic cooperation and venture into the global market
- ✓ Build a leading brand in China's animal health industry and become a global leader in animal health industry

## Our Partners (Partially listed)





📍 Distribution of major breeding bases for poultry and livestock in China in 2023  
(Data source: China animal agriculture association)




# Finished Products – Animal Healthcare



Sales Revenue of Animal Healthcare (RMB million)



Revenue Breakdown of Animal Healthcare in 2024 (By Categories)



Revenue Breakdown of Animal Healthcare in 2024 (By Products)



# Finished Products – Animal Healthcare

**100+**

Veterinary drugs that meet national standards

**30+**

Feed additives & premixtures

**6** Class II new veterinary drug certificates  
**3** Class IV new veterinary drug certificates  
**1** Class V new veterinary drug certificates

**6**

Overseas registration approvals

## Penicillin Sodium for Injection

- Launched in 2016, applicable to **livestock**
- Prompt onset, safe and stable



## Amoxicillin Soluble Powder 80%

- Launched in 2018, applicable to **poultry/aquatic**
- High concentration, cost-effective

## Amoxicillin and Clavulanate Potassium Tablets

- Launched in 2023, applicable to **pets**
- Customized APIs, highly absorbable



## Compound Amoxicillin Powder

- Launched in 2017, applicable to **livestock/poultry**
- Broad-spectrum antibacterial, well-resistant



**Flagship Products**

联治灵

邦倍林

联邦金

联克净

联立健

## Amoxicillin and Colistin Sulfate Soluble Powder

- Launched in 2020, applicable to **poultry**
- First choice for mixed secondary infection




# Intermediate Products & Bulk Medicine




## – Revenue Breakdown

In 2024, sales revenue from intermediate products increased by 14.8% to RMB2,658.7 million and bulk medicine decreased by 0.4% to RMB6,372.7 million, accounting for 19.3% and 46.3% of the Group’s total external sales, respectively



Revenue breakdown of intermediate products & bulk medicine in 2024 (By Products)

- 6-APA: RMB1,857.9 million
- Penicillin G Potassium First Crystal: RMB800.7 million
- Semi-synthetic penicillins type: RMB425.6 million
- Cephalosporins type: RMB396.2 million
- β-lactamase inhibitors type: RMB1,659.9 million
- Carbapenems type: RMB47.0 million
- Others type: RMB10.1 million



Revenue breakdown of intermediate products & bulk medicine in 2024 (By Markets)

- PRC: RMB6,388.1 million
- Europe: RMB695.6 million
- India: RMB634.3million
- Middle East: RMB73.3 million
- South America: RMB363.3 million
- Other Asian Regions: RMB633.3 million
- Other Regions: RMB243.5 million



# Intermediate Products & Bulk Medicine

## – Production Capacity



Types	Products	Designed Capacity (tonnes)	Utilization Rate	External Sales
Intermediate Products	6-APA/Penicillin G Potassium First Crystal <sup>1</sup>	20,500	100%	67.7% <sup>2</sup>
	T-Octylammonium Clavulanate	800	88.9%	N/A
Bulk Medicine	Semi-synthetic penicillins type	23,000	93.5%	90%
	Cephalosporins type	1,200	85.5%	90%
	β-lactamase inhibitors type	1,568	100%	90%

1. Currently, 6-APA and Penicillin G Potassium First Crystal are produced in the same line in Inner Mongolia Company.

2. Opening inventory is not included in calculating the percentage of external sales.



# Production Bases Under Construction

Upon completion and full production, the newly added annual output value will exceed RMB5 billion

## New Plant of The United Animal Healthcare (Inner Mongolia)



- ✓ Covers an area of 100 mu
- ✓ Major products
  - Veterinary finished products
    - Powder/premix
    - Sterile powder injection
    - Injections
    - Disinfectant
  - Pet products
    - Tablets
    - Oral liquid
    - Drops
    - Soft chews
    - Feed additives
- ✓ Expected to be completed and put into operation in 2025

## Henan Lianmu Veterinary Medicine Co., Ltd.



- ✓ Covers an area of 94 mu
- ✓ Six veterinary drug production lines
- ✓ Major products
  - Veterinary finished products
    - Powder/premix
    - Sterile powder injection
    - Large volume injection
- ✓ Expected to be completed and put into operation in 2025

## Zhuhai United Animal Healthcare Co., Ltd.



- ✓ Located in Gaolan Port, Zhuhai
- ✓ Covers an area of 100 mu
- ✓ Major products
  - Veterinary bulk medicine
    - Cephalosporins
    - Flunixin meglumine
    - Enrofloxacin
    - Special bulk medicine for all kinds of pets
  - Pet drugs
- ✓ Expected to be completed and put into operation in 2025

## Zhuhai United Laboratories (Gaolan Port) API Project



- ✓ Covers an area of 180 mu
- ✓ Major products
  - Sterile enzyme inhibitor APIs
  - Sterile cephalosporin APIs
- ✓ Expected to be completed and put into operation in 2025

## Inner Mongolia Guangda Lianfeng Biotechnology Co., Ltd.



- ✓ Major products
  - Bulk medicine
  - Dodecanedioic acid and others
- ✓ Groundbreaking ceremony in Apr 2024



# Section 4

---

R & D





# R&D Investment & Achievements

## Approved for Market Launch

- ✓ Liraglutide Injection (3ml:18mg)
- ✓ Mupirocin Ointment (2% (5g:0.1g)
- ✓ Polyvinyl Alcohol Eye Drops (1.4% (0.4ml:5.6mg))

## Application for Registration


- ✓ Insulin Degludec Injection
- ✓ Semaglutide Injection (Diabetes)

## Approved for Clinical Trial

- ✓ Clinical Trials for UBT251 Injection (CKD) approved in China and the U.S.

## Consistency Evaluation of Generic Drugs

- ✓ Imipenem and Cilastatin Sodium for Injection (0.5g; 1.0g)
- ✓ Amoxicillin and Clavulanate Potassium Tablets (0.375g)
- ✓ Amoxicillin Granules (0.125g)
- ✓ Ceftazidime for Injection (1.0g)
- ✓ Cefuroxime Sodium for Injection (0.75g; 1.5g)
- ✓ Mupirocin Ointment (2% (5g:0.1g) )
- ✓ Ceftriaxone Sodium for Injection (1.0g; 2.0g)




Note: Partially list R&D achievements from 2024 to March 2025



# R&D Pipeline

Focus on endocrine, metabolism and autoimmune, with a well-developed pipeline of diabetes and obesity drugs



★ Class I New Drug

Endocrine/Metabolism Autoimmune


Clinical trials approved in China & the U.S.

Note: Unless otherwise specified, all progress is within China



# R&D Pipeline


Develop small molecule innovative drugs in the fields of autoimmunity, metabolism, ophthalmology, anti-infection, etc.







# Expected Market Debut





## About UBT251 China Phase Ib (Overweight/Obesity) Clinical Trial

- Adopted a randomized, double-blind, placebo-controlled trial design
- To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple subcutaneous injections of UBT251 injection
- A total of 36 patients were enrolled in three different dose groups (1mg, 1mg/3mg, 1mg/3mg/6mg). Each group adopted a dose titration method, with subcutaneous injection once a week for 12 consecutive weeks

## UBT251 China Phase Ib (Overweight/Obesity) Clinical Trial Achieved Outstanding Results

**36**

36 patients were enrolled

**3 dose groups**

Each group adopted a dose titration method (1mg, 1mg/3mg, 1mg/3mg/6mg)

**12 weeks**

With subcutaneous injection once a week for 12 consecutive weeks

**-15.1%**

At the 12th week of administration, the average weight of the people who completed the study in the highest dose group decreased by 15.1% from baseline, while the average weight of people in the placebo group increased by 1.5% from baseline


- The safety profile of UBT251 was consistent with incretin-based therapies. The most common adverse events were gastrointestinal and the vast majority were mild to moderate in severity
- The clinical trial achieved the expected results, supporting its progression to the next stage of clinical study
- TUL has initiated a Phase II clinical trial for overweight/obesity in China



## TUL01101 Tablets & TUL01101 Ointment

- Class I new drug
- Selective JAK1 inhibitor
- Phase Ib clinical trial for the treatment of rheumatoid arthritis completed
- **Phase II clinical trial of moderate-to-severe atopic dermatitis indication in progress**
- **Preparation for Phase III clinical trial of topical medications for atopic dermatitis**

### Study on Safety and Tolerance of TUL01101 Tablets



pSTAT1 Inhibition Rate - Time Plot (Mean ± SD) (PDOS)



Photos on the left demonstrate the change in drug efficacy from baseline to 96-day in a subject treated with 70mg TUL01101 Tablets.


- Clinical results from phase Ia & Ib clinical trials demonstrate a favorable dose-response relationship of TUL01101 in human subjects, with significant efficacy and good safety profile observed among patients.

## TUL12101 Eye Drops


- Class I new drug
- Novel Small Molecule RASP (Reactive Aldehyde) Inhibitors
- Eye drops for the treatment of dry eye syndrome
- A clear and well-defined mechanism of action, ensuring safety and comfort
- **No other products with the same mechanism on the market in China or worldwide at present**
- The first subject was enrolled in the phase IIa clinical trial in Oct 2024



# R&D Pipeline – Animal Healthcare




# R&D Pipeline – Animal Healthcare





# Expected Market Debut

59 independent & collaborative research projects on veterinary drugs for companion and economic animals








# Section 5

---

## Outlook & Strategies



# Outlook & Strategies



- Adhere to the innovation-driven development strategy, further increase innovation investment and improve R&D efficiency
- Expand the new drug pipeline portfolio, with a focus on key therapeutic areas
- Continue to advance overseas licensing and partnerships
- Build a stronger high-end talent team and motivate innovation vitality

- Expedite the international development of all business units to reinforce our global strategic footprint
- Deepen the vertical integration of business layout, cultivate diversified business, and strengthen overall competitiveness
- Enrich the product matrix and explore potential markets
- Strengthen strategic cooperation and solidify market presence
- Advance a new framework for complementary and synergy growth across finished products, bulk medicine, animal healthcare and R&D

- Ensure robust cash flow to support our business expansion and respond to market changes
- Optimize the balance between short-term and long-term debts to manage financial costs and mitigate foreign exchange exposure
- Maximize the efficiency of capital use and improve investment returns
- Seek for low-cost Renminbi borrowings to facilitate the implementation of project financing
- Enhance enterprise value and promote long-term, healthy, and sustainable development



# Section 6

---

Appendix



# About TUL



Founded in 1990, The United Laboratories International Holdings Limited (“TUL”) is a leading comprehensive pharmaceutical company in China, mainly engaged in R&D, production and sales of pharmaceuticals. TUL was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 3933) on June 15, 2007. Currently, TUL is a constituent stock of the Hang Seng Composite Index Series and maintained at A level in the MSCI ESG Ratings, ranking at the forefront in pharmaceutical industry.


Over the past three decades, TUL has expanded from an initial product structure dominated by antibiotics to encompass biopharmaceuticals and veterinary drugs, while continuously optimizing the vertically integrated business model. With seven production bases, TUL’s product portfolio covers pharmaceutical intermediates and APIs, finished products, veterinary drugs, pharmaceutical capsules, and medical devices. Its sales network extends to nearly 80 countries and regions worldwide.

TUL is committed to expanding drug research areas and international perspective, with a comprehensive presence across multiple platforms and a focus on endocrinology, autoimmunity, high-end anti-infectives, ophthalmology, and other fields. Multiple Class I innovative drugs have entered clinical trials. To date, over 100 research projects are in progress and more than 100 patents have been obtained.

<b>1990</b> Establishment	<b>2007</b> Listed on HKEX	<b>7</b> Production Bases	<b>17,000+</b> Employees
------------------------------	-------------------------------	------------------------------	-----------------------------



# Business Model



#Product names in the same color represent the same type from upstream to downstream varieties.





# Production Bases In Operation

**Hong Kong**  
Produce **finished products**



**Zhuhai**  
Produce **bulk medicines, biological and finished products**



**Inner Mongolia**  
**Animal healthcare**  
Produce **veterinary drugs and feed additives**



**Kendor (Zhejiang)**  
Produce **medical devices**



**Zhongshan**  
Produce **finished products**



**Inner Mongolia**  
Produce **intermediate products and bulk medicines**



**Kaiping**  
Produce **empty capsule casings**



# Sales Network



## Intermediate Products & Bulk Medicine

- Team of approximately 100 employees
- Operates with eight sales territories
- Covers nearly 80 countries and regions globally
- Provides service to more than 600 clients worldwide



## Human-use Finished Products

- Team of approximately 4,000 employees, under management by medical market, OTC market and broader market
- Operates with 28 sales divisions of finished products
- Covers 23,000+ hospitals, 330,000+ health clinics and community clinics, and 230,000+ pharmacies
- International Trade Division for Finished Products has been established to expand overseas markets




## Animal Healthcare

- Established in 2014
- Team of approximately 60 employees
- Operates with seven business units and a sales network covering the entire country
- Provides service to more than 300 clients
- Established an International team and is continuously expanding



# R&D Milestones







# R&D Platforms

## A Comprehensive R&D System with Multiple Platforms

### Biological Drug

- 18 human drugs under research, including 11 Class I new drugs
- 13 veterinary drugs and pharmaceutical excipients, including 5 Class I new veterinary drugs
- Over 800 R&D and technical personnel
- Post-doctoral research station
- Guangdong Biomedical Engineering Research Center for Diabetes

### Animal Healthcare

- Established in June 2015
- 10 new veterinary drug registration certificates and 6 overseas registration approvals for animal healthcare products
- The team specializes in the fields of veterinary pharmacology, pathology, veterinary medicine, pharmaceutical engineering, etc.

### Chemical Drug

- 25 chemical new drugs under research
- Generic drug consistency evaluation projects: 8 in progress and 26 have completed
- Approx. 220 R&D personnel
- Post-doctoral research station

### Clinical Research

- Work closely with nearly 200 authoritative institutes in China that are qualified to conduct national drug clinical trials
- Nearly 110 clinical trials have been completed

### Innovative (Chemical) Drug

- Cooperation and development of small molecule innovative drug projects
- 11 Class I new drugs
- 22 partner institutes
- 70% of researchers hold master's or doctoral degrees

### External Cooperation

- Cooperate with well-known universities, research institutes and laboratories at home and abroad



## MSCI ESG Rating maintains at **Grade A**, ranking at the forefront in pharmaceutical industry

### Environmental

- ✓ Adhere to the concept of sustainable development, comprehensively build green factories
- ✓ Respond to the national carbon peaking & carbon neutrality goals, persist in promoting low-carbon development, and improve energy efficiency
- ✓ Pay attention to climate change, enhance climate risk resilience, and seize favorable climate opportunities

### Social

- ✓ Pay attention to medical accessibility, and relieve the burden of medication costs for patients
- ✓ Equipped with comprehensive systems of R&D and innovation, quality management, supply chain management, staff training and social welfare
- ✓ Establish the "United Medical Education Scholarship", involved in a series of philanthropic initiatives, like "Filial Piety Swallows" charity

### Governance

- ✓ Enhance ESG governance, and embed sustainable development principles into business operations
- ✓ Abide by business ethics, safeguard information security, and protect intellectual property rights
- ✓ Uphold professional, branding, and compliance marketing system management



PKMG China  
**Outstanding Social Pioneer**

CPHI China  
**Sustainability Influencer**

Roadshow China  
x Excellence IR  
**Best ESG Award**

2024 China International Fair  
for Trade in Services  
**Pioneer in ESG Management**

HEALTHCARE EXECUTIVE  
**TOP10 Low Carbon Pioneers  
among Chines Pharmaceutical  
Listed Companies in 2024**



让生命更有价值  
Our mission is to make life more valuable



TUL Investor Relations  
[tulir@tul.com.hk](mailto:tulir@tul.com.hk)  
<http://ir.tul.com.cn>